Approvable letter for Wyeth Pharmaceuticals osteoporosis drug (BizJournals)
The Food and Drug Administration issued a third approvable letter for Wyeth Pharmaceuticals’ experimental drug bazedoxifene, which is being developed under the brand name Viviant to prevent postmenopausal osteoporosis. (WYE)